### **Five Deadly Sins of Big Pharma**

Published on Monday, September 12, 2016 by <u>Common Dreams</u>

## **Five Deadly Sins of Big Pharma**

by

Paul Buchheit

14 Comments



A pharmacist holds a package of EpiPens epinephrine auto-injector, a Mylan product, in Sacramento, Calif., last month. Mylan said it will make available a generic version of its EpiPen, as criticism mounts over the price of its injectable medicine. (Photo: Rich Pedroncelli/AP)

For Mylan, it was a perfect plan—diabolical, unstoppable. The company made <u>changes</u> in its anti-allergy EpiPen dispenser in 2009, enough to give it <u>patent</u> protection. Then, in 2012, it began to give away free pens to <u>schools</u>, gradually making school nurses at least partly dependent on them. Meanwhile the company was successfully lobbying for the "Emergency Epinephrine Act," commonly referred to as the

"<u>EpiPen Law</u>," which encouraged the presence of epinephrine dispensers in schools. Most recently, after raising the price from \$100 to \$600, Mylan <u>announced</u> a *half-price* coupon, making itself appear generous even though the price had effectively *jumped from \$100 to \$300*.

This is capitalism at its worst, a greedy and disdainful profit-over-people system that leaves millions of Americans sick... or dead. These are the sins of the pharmaceutical industry.

#### 1. Gouging Customers

The Mylan story is just one of many. An American with cancer will face <u>bills</u> up to \$183,000 per year, even though it <u>hasn't</u> been established that the expensive treatments actually <u>extend lives</u>. A 12-week course of Sovaldi, for hepatitis, costs Gilead Sciences about \$84 and is priced at <u>\$84,000</u>.

This is an industry that can suddenly impose a <u>60,000% increase</u> on desperately ill people. Yet the pharmaceutical industry's profit margin is matched only by the unscrupulous <u>financial industry</u> for the highest corporate profit margin.

#### 2. Disposing of People Who Can't Afford Medication

A Forbes writer <u>summarizes</u>: "Somewhere, right now, a cash-strapped parent or budget-limited patient with a severe allergy will skip acquiring an EpiPen. And someday, they will need it in a life-threatening situation...and they won't have it. And they will die."

A recent <u>Health Affairs</u> study concluded that since 2004 our medical dollars have been "increasingly concentrated on the wealthy." As a result the richest 1% of American males live nearly <u>15 years longer</u> than the poorest 1% (10 years for women). The high cost of medication is one of the factors leading to early death.

#### 3. Gouging Us a Second Time

We're paying twice for outrageously overpriced medications, both directly and with our tax dollars. The average medical insurance deductible has increased <u>67 percent</u> since 2010, and most Medicare patients still face <u>out-of-pocket costs</u> of \$7,000 or more a year.

Over \$5 billion of our tax dollars was <u>spent</u> by Medicare and Medicaid in 2014 on just two drugs (Sovaldi and Harvoni). Pharmaceutical lobbyists have rigged the system to prevent Medicare from <u>negotiating</u> for lower drug prices.

Not satisfied with Medicare-related abuses, Purdue Pharmaceuticals began <u>targeting</u> troubled post-9/11 veterans with expensive and addicting opioid medications, and within ten years a third of the Army's soldiers were hooked on prescription drugs.

#### 4. Stealing Our Research

# The pharmaceutical industry receives most of its <u>basic research</u> funding from the taxpayers, and 75 percent of the most <u>innovative drugs</u> were initially funded by the National Institutes of Health.

Dean Baker <u>notes</u> that the U.S. is unique in giving drug companies patent monopolies on drugs that are essential for people's health and lives. An example is genetically engineered <u>insulin</u>, which due to patent protection cannot be made generically, and as a result can <u>cost</u> a patient up to \$5,000 a year, many times more than a <u>patent-expired</u> version. Another example is the anti-parasite drug <u>Daraprim</u>, which has been on the market for 62 years, yet was appropriated by the now-infamous Martin Shkreli and price-hiked from \$13.50 to \$750.00.

A common excuse for pharmaceutical greed is the cost of research and development. But the industry spends almost \$20 on <u>marketing</u> for every dollar spent on <u>R&D</u>. Meanwhile, Big Pharma has <u>cut</u> nearly 150,000 jobs since 2008, mostly in R&D.

#### 5. Cheating on Taxes

<u>Three</u> of the world's <u>largest</u> pharmaceutical companies, with over \$20 billion in combined profits last year, claimed nearly \$9 billion in U.S. <u>losses</u> despite having nearly half their sales in the United States.

Other major drug companies use the notorious *inversion* procedure to skip out on taxes. <u>AbbVie</u> has done it. Pfizer tried. And <u>Mylan</u>, along with all its other transgressions, ditched the U.S. for the Netherlands, despite having its employees and facilities in West Virginia. Adding a further touch of hypocrisy, Mylan sought U.S. government <u>help</u> when another company tried to buy it out.

Patriotism is a beautiful thing to corporations when it protects their profits.

This work is licensed under a Creative Commons Attribution-Share Alike 3.0 License



<u>Paul Buchheit</u> is a college teacher, an active member of US Uncut Chicago, founder and developer of social justice and educational websites (UsAgainstGreed.org, PayUpNow.org, RappingHistory.org), and the editor and main author of "<u>American Wars: Illusions and Realities</u>" (Clarity Press). He can be reached at <u>paul@UsAgainstGreed.org</u>.

http://www.commondreams.org/views/2016/09/12/five-deadly-sins-big-pharma